JP2012509264A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509264A5 JP2012509264A5 JP2011536397A JP2011536397A JP2012509264A5 JP 2012509264 A5 JP2012509264 A5 JP 2012509264A5 JP 2011536397 A JP2011536397 A JP 2011536397A JP 2011536397 A JP2011536397 A JP 2011536397A JP 2012509264 A5 JP2012509264 A5 JP 2012509264A5
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- lactide
- weight
- ester
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims 24
- 229920000642 polymer Polymers 0.000 claims 24
- 239000007943 implant Substances 0.000 claims 20
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical group C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 10
- 229960003679 brimonidine Drugs 0.000 claims 10
- 150000002148 esters Chemical class 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 229920002988 biodegradable polymer Polymers 0.000 claims 6
- 239000004621 biodegradable polymer Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 229920003178 (lactide-co-glycolide) polymer Polymers 0.000 claims 4
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 229960001724 brimonidine tartrate Drugs 0.000 claims 4
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/272,548 US9095506B2 (en) | 2008-11-17 | 2008-11-17 | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US12/272,548 | 2008-11-17 | ||
| PCT/US2009/063490 WO2010056598A2 (en) | 2008-11-17 | 2009-11-06 | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014143227A Division JP2014184348A (ja) | 2008-11-17 | 2014-07-11 | 生分解性α−２アゴニストポリマー性インプラントおよびその治療用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012509264A JP2012509264A (ja) | 2012-04-19 |
| JP2012509264A5 true JP2012509264A5 (cg-RX-API-DMAC7.html) | 2012-12-20 |
| JP5580832B2 JP5580832B2 (ja) | 2014-08-27 |
Family
ID=41698087
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536397A Expired - Fee Related JP5580832B2 (ja) | 2008-11-17 | 2009-11-06 | 生分解性α−２アゴニストポリマー性インプラントおよびその治療用途 |
| JP2014143227A Pending JP2014184348A (ja) | 2008-11-17 | 2014-07-11 | 生分解性α−２アゴニストポリマー性インプラントおよびその治療用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014143227A Pending JP2014184348A (ja) | 2008-11-17 | 2014-07-11 | 生分解性α−２アゴニストポリマー性インプラントおよびその治療用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (7) | US9095506B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2355795B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5580832B2 (cg-RX-API-DMAC7.html) |
| AU (3) | AU2009314266A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2743837C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2624448T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010056598A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US8673341B2 (en) * | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
| US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US20100104654A1 (en) | 2008-10-27 | 2010-04-29 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| CA2762536C (en) | 2009-05-18 | 2019-05-21 | Dose Medical Corporation | Drug eluting ocular implant |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| CA2764063C (en) | 2009-06-03 | 2019-05-14 | Forsight Labs, Llc | Anterior segment drug delivery |
| JP5982287B2 (ja) | 2009-11-09 | 2016-08-31 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 発毛を刺激する組成物および方法 |
| ES2561083T3 (es) | 2010-01-22 | 2016-02-24 | Allergan, Inc. | Implantes intracamerales de agentes terapéuticos de liberación sostenida |
| US9668915B2 (en) | 2010-11-24 | 2017-06-06 | Dose Medical Corporation | Drug eluting ocular implant |
| US20120213840A1 (en) * | 2011-02-18 | 2012-08-23 | Valeant International (Barbados) Srl | Ocular strips |
| EP2701682A1 (en) | 2011-04-29 | 2014-03-05 | Allergan, Inc. | Solvent cast film sustained release latanoprost implant |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| ES2912370T3 (es) | 2011-09-14 | 2022-05-25 | Forsight Vision5 Inc | Aparato para inserción ocular |
| US20180126033A9 (en) | 2012-03-14 | 2018-05-10 | MAM Holdings of West Florida, L.L.C. | Collagen compositions and uses for biomaterial implants |
| CA2867203C (en) * | 2012-03-16 | 2016-09-20 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| JP5883539B2 (ja) | 2012-03-16 | 2016-03-15 | ザ・ジョンズ・ホプキンス・ユニバーシティー | Ｈｉｆ−１阻害剤の送達のための放出制御製剤 |
| JP6298068B2 (ja) | 2012-10-26 | 2018-03-20 | フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． | 眼に対する薬物徐放用眼科システム |
| HK1218850A1 (zh) * | 2013-02-15 | 2017-03-17 | Allergan, Inc. | 持续药物递送植入物 |
| KR20150141972A (ko) * | 2013-04-12 | 2015-12-21 | 알레간 인코포레이티드 | 지방 감소를 위한 비마토프로스트, 비마토프로스트 유사체, 프로스타미드 및 프로스타글란딘의 서방출 |
| SG11201603383VA (en) | 2013-10-31 | 2016-05-30 | Allergan Inc | Prostamide-containing intraocular implants and methods of use thereof |
| MX2016007345A (es) * | 2013-12-06 | 2016-12-09 | Envisia Therapeutics Inc | Implante intracameral para el tratamiento de una condicion ocular. |
| EP3145549A4 (en) * | 2014-05-23 | 2018-02-14 | Ocular Technologies Sàrl | Topical formulations and uses thereof |
| EP3677229A1 (en) | 2014-05-29 | 2020-07-08 | Glaukos Corporation | Implants with controlled drug delivery features |
| EP3179982B1 (en) * | 2014-07-28 | 2023-07-19 | Sun Pharma Advanced Research Company Ltd | Method of increasing bioavailability and/or prolonging ophthalmic action of a drug |
| MX2017001863A (es) | 2014-08-13 | 2017-07-17 | Univ Johns Hopkins | Nanoparticulas cargadas con glucocorticoides para prevencion de rechazo de aloinjerto corneal y neovascularizacion. |
| SG10201903210WA (en) | 2014-12-15 | 2019-05-30 | Univ Johns Hopkins | Sunitinib Formulations and Methods for Use Thereof in Treatment of Ocular Disorders |
| WO2016118506A1 (en) | 2015-01-20 | 2016-07-28 | The Johns Hopkins University | Compositions for the sustained release of anti-glaucoma agents to control intraocular pressure |
| ES2830177T3 (es) | 2015-03-06 | 2021-06-03 | Aerie Pharmaceuticals Inc | Aplicadores de implantes |
| GB201505527D0 (en) | 2015-03-31 | 2015-05-13 | Jmedtech Pte Ltd | Composition |
| US20160296532A1 (en) | 2015-04-13 | 2016-10-13 | Forsight Vision5, Inc. | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent |
| WO2017015604A1 (en) | 2015-07-23 | 2017-01-26 | Envisia Therapeutics, Inc. | Intravitreal drug delivery systems for the treatment of ocular conditions |
| EP3943072A1 (en) * | 2015-07-27 | 2022-01-26 | Sun Pharma Advanced Research Company Ltd | Drug loaded nanoresin particles |
| WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| HK1257499A1 (zh) | 2015-11-12 | 2019-10-25 | Graybug Vision, Inc. | 用於治疗的聚集性微粒 |
| US9579350B1 (en) | 2016-02-25 | 2017-02-28 | MAM Holdings of West Florida, L.L.C. | Human amniotic fluid preparation having long-term stability |
| US20190022016A1 (en) | 2016-03-02 | 2019-01-24 | The Johns Hopkins University | Compositions for sustained release of anti-glaucoma agents to control intraocular pressure |
| CA3022830A1 (en) | 2016-04-20 | 2017-10-26 | Harold Alexander Heitzmann | Bioresorbable ocular drug delivery device |
| WO2018045386A1 (en) | 2016-09-02 | 2018-03-08 | Envisia Therapeutics, Inc. | Implant applicators |
| AU2018240462C1 (en) | 2017-03-23 | 2022-12-08 | Graybug Vision, Inc. | Drugs and compositions for the treatment of ocular disorders |
| MX2019013363A (es) | 2017-05-10 | 2020-01-13 | Graybug Vision Inc | Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica. |
| JP2020536955A (ja) | 2017-10-06 | 2020-12-17 | ファウンドリー セラピューティクス， インコーポレイテッド | 治療剤の制御放出のための埋込み可能なデポー |
| EP3737433A1 (en) | 2018-01-08 | 2020-11-18 | Foundry Therapeutics, Inc. | Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents |
| EP3793536A1 (en) | 2018-05-12 | 2021-03-24 | Foundry Therapeutics, Inc. | Implantable polymer depots for the controlled release of therapeutic agents |
| JP2021529747A (ja) * | 2018-06-25 | 2021-11-04 | タイタン ファーマシューティカルズ インコーポレイテッド | 親油性又は両親媒性医薬物質の放出のためのインプラント |
| WO2020047013A1 (en) | 2018-08-28 | 2020-03-05 | Foundry Therapeutics, Inc. | Polymer implants |
| JP7570342B2 (ja) | 2019-03-05 | 2024-10-21 | アエリエ ファーマシューティカルズ インコーポレイテッド | 眼の疾患又は障害を治療するための医薬組成物 |
| BR112023001073A2 (pt) | 2020-07-21 | 2023-03-07 | Allergan Inc | Implante intraocular com alto carregamento de prostamida |
| AU2023355823A1 (en) | 2022-10-05 | 2025-04-17 | Mireca Medicines Gmbh | MICROPARTICLE AND IMPLANT FORMULATIONS FOR cGMP ANALOG THERAPY |
| WO2025179071A1 (en) * | 2024-02-20 | 2025-08-28 | Bausch + Lomb Ireland Limited | Sustained-release drug delivery compositions for treating ocular diseases |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2054102A (en) | 1936-09-15 | Voting machine | ||
| NL64744C (cg-RX-API-DMAC7.html) | 1940-03-09 | |||
| US2401708A (en) | 1943-01-19 | 1946-06-04 | Eastman Kodak Co | Range finder |
| US2401408A (en) | 1944-05-03 | 1946-06-04 | Harold S Bixby | Lock for fluorescent lamps |
| US2743837A (en) | 1953-06-01 | 1956-05-01 | Leon J Cook | Lead sleeve expanding device |
| US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| JPS58126435U (ja) * | 1982-02-19 | 1983-08-27 | オリンパス光学工業株式会社 | Ｔｔｌオ−トストロボ用絞り制御回路 |
| US4521210A (en) * | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
| US6309669B1 (en) * | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
| US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| US5264188A (en) * | 1991-01-22 | 1993-11-23 | Phillips Petroleum Company | Multi-stage hydrotreating process and apparatus |
| US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6369116B1 (en) * | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
| US6194415B1 (en) * | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| US5856329A (en) * | 1995-06-28 | 1999-01-05 | Allergan | Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
| US6066675A (en) * | 1996-09-13 | 2000-05-23 | The Regents Of The University Of California | Method for treatment of retinal diseases |
| KR20010014384A (ko) | 1997-07-02 | 2001-02-26 | 모리타 다카카즈 | 폴리락트산 공막 플러그 |
| DE69827138T2 (de) * | 1997-08-11 | 2006-02-23 | Allergan, Inc., Irvine | Steriles Retinoid enthaltendes biodegradierbares Implantat mit verbesserter Biokompatibilität und Verfahren zu dessen Herstellung |
| ES2240180T3 (es) * | 1999-10-21 | 2005-10-16 | Alcon Inc. | Administracion sub-tenon de medicamentos. |
| US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| US20010049369A1 (en) * | 2000-02-10 | 2001-12-06 | Jablonski Monica M. | Brimonidine compositions and methods for retinal degeneration |
| US6692759B1 (en) * | 2000-06-28 | 2004-02-17 | The Regents Of The University Of California | Methods for preparing and using implantable substance delivery devices |
| AU2002248284A1 (en) | 2000-11-01 | 2002-08-06 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
| ES2250504T3 (es) * | 2000-11-29 | 2006-04-16 | Allergan Inc. | Prevencion del rechazo de injerto en el ojo. |
| JP5170935B2 (ja) * | 2001-11-14 | 2013-03-27 | デュレクト コーポレーション | 注入可能なデポー組成物 |
| US20060216328A1 (en) | 2002-03-18 | 2006-09-28 | Kis Gyorgy L | Topical composition comprising a cyclofructan, a carrier and a drug |
| US20040001889A1 (en) * | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
| JP4463681B2 (ja) * | 2002-07-15 | 2010-05-19 | アルコン，インコーポレイテッド | 眼内使用のための非ポリマー親油性薬学的インプラント組成物 |
| US6899717B2 (en) * | 2002-09-18 | 2005-05-31 | Allergan, Inc. | Methods and apparatus for delivery of ocular implants |
| PL376347A1 (en) * | 2002-10-08 | 2005-12-27 | Allergan, Inc. | Method of using (2-imidazolin-2-ylamino) qinoxalines in the treatment of dementia and parkinsons |
| PL377333A1 (pl) * | 2002-11-06 | 2006-01-23 | Alza Corporation | Preparaty depot o kontrolowanym uwalnianiu |
| AR042917A1 (es) | 2003-01-24 | 2005-07-06 | Control Delivery Sys Inc | Dispositivo de liberacion sostenida para la administracion ocular de agentes adrenergicos y uso de agentes adrenergicos para su preparacion |
| JP2005035235A (ja) * | 2003-07-18 | 2005-02-10 | Noritsu Koki Co Ltd | 画像露光装置 |
| US20050131372A1 (en) * | 2003-12-10 | 2005-06-16 | Kimberly-Clark Worldwide, Inc. | Absorbent articles with removable protective wing portions |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US7799336B2 (en) * | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US20050244471A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
| US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
| US20060182781A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
| US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US7135391B2 (en) * | 2004-05-21 | 2006-11-14 | International Business Machines Corporation | Polycrystalline SiGe junctions for advanced devices |
| US7931909B2 (en) * | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| US8802128B2 (en) | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| EA202192521A1 (ru) | 2019-04-23 | 2022-02-08 | Рэйли С.Р.Л. | Модульное ограждение, пригодное для установки с переменным наклоном |
| US11902105B2 (en) | 2022-05-24 | 2024-02-13 | Red Hat, Inc. | Interactive graphical user interface for visualizing flow data in a programmable network switch |
-
2008
- 2008-11-17 US US12/272,548 patent/US9095506B2/en active Active
-
2009
- 2009-11-06 EP EP09799446.1A patent/EP2355795B1/en active Active
- 2009-11-06 ES ES09799446.1T patent/ES2624448T3/es active Active
- 2009-11-06 WO PCT/US2009/063490 patent/WO2010056598A2/en not_active Ceased
- 2009-11-06 JP JP2011536397A patent/JP5580832B2/ja not_active Expired - Fee Related
- 2009-11-06 CA CA2743837A patent/CA2743837C/en active Active
- 2009-11-06 AU AU2009314266A patent/AU2009314266A1/en not_active Abandoned
-
2014
- 2014-07-11 JP JP2014143227A patent/JP2014184348A/ja active Pending
-
2015
- 2015-08-03 US US14/816,401 patent/US9522113B2/en not_active Expired - Fee Related
-
2016
- 2016-07-01 AU AU2016204582A patent/AU2016204582A1/en not_active Abandoned
- 2016-12-19 US US15/383,079 patent/US9861576B2/en active Active
-
2018
- 2018-01-08 US US15/864,990 patent/US10471004B2/en active Active
- 2018-04-12 AU AU2018202557A patent/AU2018202557B2/en not_active Ceased
-
2019
- 2019-11-11 US US16/679,737 patent/US10842739B2/en not_active Expired - Fee Related
-
2020
- 2020-11-06 US US17/091,434 patent/US20210161809A1/en not_active Abandoned
-
2022
- 2022-07-15 US US17/812,893 patent/US20230285279A1/en not_active Abandoned